Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery.

Cancer medicine - 1 Jan 2015

Tazi Karim, Hathaway Amanda, Chiuzan Cody, Shirai Keisuke

Abstract excerpt

UNLABELLED: Historically, melanoma with brain metastases has a poor prognosis. In this retrospective medical record review, we report the outcome of patients with stage IV melanoma with brain metastases treated with ipilimumab and brain stereotactic radiosurgery (SRS). All patients with metastatic melanoma treated with ipilimumab from June 2010 to September 2012 were identified and stratified by presence (A) or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Brain Neoplasms
Share to Ipilimumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins B-raf

Share to Radiosurgery

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 25164960
DOI: 10.1002/cam4.315
PMCID: PMC4312111

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery.PMID 25164960Read ↗

Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies.Semantic proximity Read ↗

Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.Semantic proximity Read ↗

Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.Semantic proximity Read ↗

Melanoma brain metastasis: overview of current management and emerging targeted therapies.Semantic proximity Read ↗

Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases.Semantic proximity Read ↗

Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.Semantic proximity Read ↗

The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.Semantic proximity Read ↗

Melanoma Brain Metastasis, Prognostic Factors, and Survival Outcomes After First Metastatic Line Therapy: A Monocentric Retrospective Study.Semantic proximity Read ↗

Systemic therapies for melanoma brain metastases: which drug for whom and when?Semantic proximity Read ↗

Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in MelanomaSemantic proximity Read ↗

Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.Semantic proximity Read ↗

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.